- Home
- FMAO vs LRMR Comparison
FMAO vs LRMR Comparison
Compare FMAO & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMAO | LRMR |
|---|---|---|
| Founded | 1897 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.1M | 455.8M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FMAO | LRMR |
|---|---|---|
| Price | $30.60 | $3.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $28.50 | $16.50 |
| AVG Volume (30 Days) | 106.0K | ★ 2.3M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | ★ 27.89 | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.20 | $1,816.14 |
| P/E Ratio | $43.53 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.89 | $2.72 |
| 52 Week High | $30.90 | $6.42 |
Technical Indicators
Market Signals| Indicator | FMAO | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 71.85 | 39.75 |
| Support Level | $25.94 | $3.12 |
| Resistance Level | N/A | $3.74 |
| Average True Range (ATR) | 0.70 | 0.29 |
| MACD | 0.18 | 0.02 |
| Stochastic Oscillator | 89.31 | 29.36 |
Price Performance
Historical ComparisonAbout FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company based in Ohio. The company is engaged in one segment which is commercial banking. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.